Poniard appoints Gary Lyons to board
This article was originally published in Scrip
Gary Lyons has joined the board of directors at Poniard Pharmaceuticals (US), a biopharmaceutical company focused on oncology therapies. His appointment brings the number of directors on the board to 10. Mr Lyons has been a consultant to Poniard since April. He has served as a director at Neurocrine Biosciences since February 1993, and held various executive positions with the company, including president and CEO, from February 1993 until January 2008.